Temporal trends in the proportion of "cure" in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: A population-based study

Pediatric Blood & Cancer
Daniel DrozdovAurélien Belot

Abstract

Survival probability in children, adolescents, and young adults with chronic myeloid leukemia (CML) has dramatically improved during recent years. Tyrosine kinase inhibitors (TKI), targeted drugs developed for patients with CML, were introduced in 2001 in England. We here quantify the trends in the "cure" proportion according to the year of diagnosis. We included all children, adolescents, and young patients with CML (0 to 24 years) diagnosed in England during 1980 to 2005. We fitted mixture cure models to estimate the "cure" proportion and the median survival time among the "uncured" patients according to the year of diagnosis, adjusted for age at diagnosis. The "cure" proportion increased dramatically between 1980 and 2005, from under 10% to over 80%, while conversely, the median survival time of "uncured" patients decreased slightly between 1980 and 1999, with the trend from 2000 being uncertain. The striking improvement of the "cure" fraction in young patients with CML since the early 1980s is concomitant with improvement of treatment, especially the allogeneic hematopoietic stem-cell transplant and, later, the introduction of TKI. The trends over the last years (2000-2005) remain, however, uncertain and would benefit from ...Continue Reading

References

Jul 15, 1998·International Journal of Cancer. Journal International Du Cancer·A VerdecchiaF Berrino
Feb 12, 2008·European Journal of Epidemiology·Theodora Bejan-AngoulvantLaurent Remontet
Jul 3, 2008·British Journal of Cancer·A ShahM P Coleman
Jan 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Meinolf SuttorpKirk R Schultz
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric MillotFrançois Guilhot
Jun 8, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Megan OthusJohn J Crowley
May 2, 2013·Haematologica·Christian Michel Zwaan, Richard Sposto
Jun 22, 2013·British Journal of Haematology·Anjali ShahPaul C Lambert
Sep 18, 2013·Cancer Epidemiology·X Q YuP W Dickman
Jul 1, 2014·British Journal of Haematology·Josu de la FuenteUNKNOWN International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee
Mar 31, 2015·British Journal of Haematology·Niklas GunnarssonAnders Själander
May 31, 2016·The Lancet Oncology·Annalisa TramaUNKNOWN EUROCARE-5 Working Group
Jun 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hannah BowerTherese M-L Andersson
Nov 15, 2016·Best Practice & Research. Clinical Haematology·François-Xavier Mahon
Sep 6, 2017·Journal of Theoretical Biology·Daniel KochAlexander Gebharter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Xiang-Long LiTing Liu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Stacie B DusetzinaNancy L Keating
Hematology/oncology Clinics of North America
Andrew J Innes, Jane Apperley
© 2022 Meta ULC. All rights reserved